Development · 26 Aug 2026

Apollo Hospitals transitioned its flagship oncology unit at Teynampet into a comprehensive multi-speciality hospital with 300 beds including 51 critical care beds, 5 operating theatres, and 1 Cath Lab.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

thehindubusinessline.com26 Aug 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Apollo Hospitals Enterprise

₹8,133.50

▼ -0.39%

Close (EOD), as of 1 Oct 2026 · source

Apollo Hospitals Enterprise: results, dividends, orders, the full cited record →

More on Apollo Hospitals Enterprise

Pharma stocks are picking up pace, with the sector continuing to show a strong overall technical setup despite the possibility of short-term profit booking.

2 Oct 2026 · 1 publisher

Hospital stocks extended losses for a second session on October 1 as concerns over potential medicine pricing controls continued to weigh on the sector.

2 Oct 2026 · 1 publisher

Yatharth Hospital shares slumped as much as 5.92 per cent to Rs 1,040.15, while Apollo Hospitals declined 5.69 per cent to Rs 8,207.05.

30 Sep 2026 · 1 publisher

Hospital stocks, including Apollo Hospitals, Fortis Healthcare, and Krishna Institute of Medical Sciences (KIMS), fell up to 6% after the Supreme Court raised concerns over steep mark-ups on medicines sold through corporate hospitals.

30 Sep 2026 · 2 publishers

Hospital stocks Apollo Hospitals Ltd., Fortis Healthcare Ltd., Max Healthcare Ltd., Krishna Institute of Medical Sciences Ltd., Narayana Health Ltd., and Global Health Ltd. were trading with losses between 5% to 6% on Wednesday, September 30.

30 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.